Effect of Polypharmacy on Long-Term Mortality After Percutaneous Coronary Intervention
Section snippets
Methods
The Coronary Revascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/CABG registry Cohort-3 is a physician-initiated, noncompany-sponsored, multicenter registry enrolling consecutive patients who underwent first coronary revascularization with PCI or isolated CABG without combined non-coronary surgery among 22 Japanese centers between January 2011 and December 2013 (Supplemental Appendix). The design and patient enrollment of the CREDO-Kyoto PCI/CABG registry Cohort-3 were
Results
Among the study population, the median number of medications was 6 (IQR: 5 to 8), and 10,821 patients (88.0%) had 5 or more medications (Figure 2). The detailed information of the medications was shown in Table 2. The median number of antithrombotic medications was 2, the median number of lipid modifying medications was 1, the median number of medications for hypertension and/or heart failure was 2, and the median number of medications for peptic ulcer was 1. Most of medications were those
Discussion
The main findings of this real-world study evaluating polypharmacy and long-term mortality in patients who underwent PCI were as follows; (1) The median number of medication at discharge from index PCI hospitalization was 6, and 88.0% of the patients were on >=5 medications; (2) Main medications consisted of antiplatelet medications, lipid modifying medications, medications for hypertension and/or heart failure, and medications for peptic ulcer, and there were only a few medications prescribed
Disclosures
Dr. Morimoto reports lecturer's fees from Bayer, Daiichi Sankyo, Japan Lifeline, Kyocera, Mitsubishi Tanabe, Novartis, and Toray, and the manuscript fees from Bristol-Myers Squibb and Kowa, and served advisory boards for Asahi Kasei, Boston Scientific, Bristol-Myers Squibb, and Sanofi. Dr. Shiomi reports personal fees from Abbott Vascular, Boston Scientific, and Daiichi Sankyo. Dr. Furukawa reports honoraria from Ono Pharmaceutical, Novartis, Daiichi Sankyo, Bayer, Otsuka Pharmaceutical, Kowa,
Acknowledgment
We appreciate the support and collaboration of the co-investigators participating in the CREDO-Kyoto PCI/CABG Registry Cohort-3. We are indebted to the clinical research coordinators for data collection.
References (12)
- et al.
Comparison of outcomes of percutaneous coronary intervention versus coronary artery bypass grafting among patients with three-vessel coronary artery disease in the new-generation drug- eluting stents era (from CREDO-kyoto PCI/CABG registry cohort-3)
Am J Cardiol
(2021) - et al.
Percutaneous coronary intervention versus coronary artery bypass grafting among patients with unprotected left main coronary artery disease in the new-generation drug-eluting stents era (from the CREDO-kyoto PCI/CABG registry cohort-3)
Am J Cardiol
(2021) - et al.
Increasing polypharmacy—an individual-based study of the Swedish population 2005-2008
BMC Clin Pharmacol
(2010) - et al.
Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands
Arch Intern Med
(2008) - et al.
The interaction of patient perception of overmedication with drug compliance and side effects
J Gen Intern Med
(1998) - et al.
Precipitating factors for delirium in hospitalized elderly persons—predictive model and interrelationship with baseline vulnerability
JAMA
(1996)
Cited by (2)
Polypharmacy in cardiorenal syndrome patients
2023, Clinical NephrologyPrognostic Impact of Multiple Drug Use at Discharge in Patients Hospitalized with Heart Failure
2023, International Heart Journal
Funding: This work was supported by an educational grant from the Research Institute for Production Development (Kyoto, Japan).